<DOC>
	<DOCNO>NCT02923947</DOCNO>
	<brief_summary>The purpose study assess effect severe renal impairment level AZD9291 blood patient advance solid tumour compare patient normal renal function .</brief_summary>
	<brief_title>Study Assess Osimertinib Patients w/ Adv Solid Tumours &amp; Normal Kidney Function Severe Kidney Impairment</brief_title>
	<detailed_description>This 3-part study ( Part A , Part B continue access ) patient advance solid tumour ( exclude lymphoma ) refractory standard therapy standard therapy exist . Part A non-randomised , open-label , parallel group , multi-centre design investigate pharmacokinetics ( PK ) single dose osimertinib patient severe renal impairment compare patient normal renal function . Patients severe renal impairment recruit normal renal function allow cohort match closely possible term demographic characteristic ( ie , age , body mass index [ BMI ] sex ) . Approximately 16 patient ( 8 severe renal impairment 8 normal renal function ) plan enrol obtain least 12 evaluable patient ( 6 severe renal impairment 6 normal renal function ) Part A . A patient severe renal impairment ( measure Cockcroft-Gault equation ) define creatinine clearance ( CrCl ) &lt; 30 mL/min whilst patient normal renal function CrCl ≥90 mL/min . Both severe renal impairment normal renal function patient recruit group match age , sex , BMI maximum extent possible . In Part A , patient receive single oral dose osimertinib 80 mg ( give tablet ) . Where possible , patient check clinic Day -1 , even prior dosing ( Day 1 ) , remain resident 24 hour dose osimertinib ( Day 2 ) collection blood sample 24-hour pooled urine PK analysis time . Samples analyse determine concentration osimertinib metabolite ( AZ5104 AZ7550 ) plasma , urine , plasma ultrafiltrate ( PUF ) . Patients return clinic outpatient assessment Day 3 ( 48 hour ) , Day 4 ( 72 hour ) , Day 6 ( 120 hour ) , Day 8 ( 168 hour ) Day 10 ( 216 hour ) . Part B allow patient severe renal impairment , complete Part A , continue receive osimertinib 80 mg daily 12 week provide additional safety data . Patients start Part B last PK sample collect Part A ( ie , 216 hour receive single dose osimertinib Part A ) . If patient immediately continue Part B , discuss case case basis AstraZeneca physician representative . Patients enter Part B , weekly clinic visit first 3 week ; thereafter visit every 3 week Week 12 . Safety assessment collect formal evaluation efficacy . At end Part B , patient severe renal impairment deem gain clinical benefit osimertinib enter continue access phase . Patients normal renal function enter continue access phase immediately complete Part A ( ie , collection last PK sample schedule Day 10 Part A ) . During continued access phase , patient may continue take osimertinib 80 mg daily , patient Investigator deem appropriate , time disease progress , Investigator believe patient longer derive clinical benefit , patient stop take osimertinib reason . No clinical data , serious adverse event ( SAEs ) may relate investigational product ( IP ) , collect phase .</detailed_description>
	<mesh_term>Osimertinib</mesh_term>
	<criteria>Inclusion criterion : 1 . For inclusion patient severe renal impairment patient must stable severe renal impairment ( CrCl &lt; 30 mL/min screening ) , least 2 month prior study . 2 . For inclusion patient normal renal function , patient must CrCl ≥90 mL/min screening . 3 . &gt; 18 year old 4 . Histological cytological confirmation solid , malignant tumour ( exclude lymphoma ) refractory standard therapy standard therapy exist . Tumours inhibition EGFR pathway consider relevant Investigator mandate encourage . 5 . ECOG performance status ≤2 6 . Life expectancy ≥12 week 7 . BMI 1835 . 8 . Females use adequate contraceptive measure must negative pregnancy test prior dose childbearing potential must evidence nonchild bear potential 9 . Males use barrier contraception 6 month last study drug take . Exclusion criteria 1 . Participation another clinical study IP last 14 day ( long period , depend agent use ) . 2 . Treatment follow : Treatment 1st 2nd generation EGFRTKI within 8 day approximately 5 halflives , prior first dose study drug . Any cytotoxic chemotherapy , investigational agent anticancer drug within 14 day first dose study drug . Osimertinib present study previously receive 3rd generation EGFRTKI ( eg , CO 1686 ) . Major surgery within 4 week first dose study drug . Radiotherapy limit field radiation palliation within 1 week first dose study treatment Currently receive medication herbal supplement know potent inducer CYP3A4 . Patients Part B continue access must avoid concomitant use medication , herbal supplement and/or ingestion food know potent inducer effect CYP3A4 . 3 . Patients severe renal impairment : use concurrent medication know affect CrCl within 7 day first dose 4 . Unresolved toxicity prior therapy great CTCAE Grade 1 time start study treatment ; exception alopecia Grade 2 prior platinumtherapy relate neuropathy 5 . Spinal cord compression brain metastasis , unless asymptomatic , stable require steroid least 4 week prior start study treatment 6 . Inadequate bone marrow reserve organ function demonstrate follow laboratory value : Absolute neutrophil count &lt; 1.5 x 109/L Platelet count &lt; 100 x 109/L Haemoglobin &lt; 90 g/L ALT &gt; 2.5 time ULN demonstrable liver metastasis &gt; 5xULN presence liver metastases AST &gt; 2.5xULN demonstrable liver metastasis &gt; 5xULN presence liver metastases Total bilirubin &gt; 1.5 time ULN liver metastases &gt; 3xULN presence liver metastases 7 . Any following cardiac criterion : Mean rest QT interval QTcF &gt; 470 msec , obtain 3 ECGs . Abnormalities rhythm , conduction morphology rest ECG Any factor increase risk QTc prolongation risk arrhythmic event heart failure , hypokalaemia , congenital long QT syndrome , family history long QT syndrome unexplained sudden death 40 year age concomitant medication know prolong QT interval 8 . Unable swallow oral medication patient GI disorder significant GI resection . 9 . Medical history interstitial lung disease ( ILD ) , druginduced ILD , radiation pneumonitis require steroid treatment , evidence clinically active ILD . 10 . Severe portal hypertension surgical portosystemic shunt . 11 . Kidney transplant 12 . On dialysis</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>130 Years</maximum_age>
	<verification_date>October 2016</verification_date>
	<keyword>Pharmacokinetics ,</keyword>
	<keyword>Renal impairment ,</keyword>
	<keyword>Safety assessment ,</keyword>
	<keyword>Solid tumour ,</keyword>
	<keyword>EGFRm+</keyword>
	<keyword>EGFRm+/T790M+ inhibitor</keyword>
</DOC>